Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Tanso Biosciences is a private Japan-based biotech and drug discovery services company focused on G protein-coupled receptor (GPCR) biology. The company commercializes a proprietary high-sensitivity GPCR functional assay platform that supports panel assays, concentration-response studies, off-target profiling, orphan receptor analysis, and custom assay development. Its platform covers hundreds of validated human and mouse GPCR targets, including difficult Gi/o- and G12/13-coupled receptors, and is used by pharmaceutical, biotech, food industry, and academic customers. Tanso originated as an academic spin-off from researchers at The University of Tokyo and operates under an exclusive license to core assay-related intellectual property from the university. The business appears centered on enabling and de-risking early-stage GPCR drug discovery rather than advancing a disclosed internal therapeutic pipeline.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Tanso Biosciences.